NCT Number: NCT06648733
The transition of palliative care patients from inpatient to outpatient care is aimed to be improved through structured pharmaceutical discharge management by a trained pharmacist. This data will be compared with retrospective cases.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Münster, North Rhine-Westphalia, 48149, Germany
Location status: Recruiting
Christoph Klaas, Dr. rer. nat.
PRINCIPAL_INVESTIGATOR
Constanze Rémi, Dr. rer. biol. hum.
SUB_INVESTIGATOR
Florian Bernhardt
SUB_INVESTIGATOR
Janina Krüger, Dr. med.
SUB_INVESTIGATOR
Philipp Lenz, Prof. Dr. med.
CONTACT
Sofie May
SUB_INVESTIGATOR
As part of a prospective observational study with a retrospective comparison group, a pharmacist should, on request, check the discharge medication planned by the primary care physicians before discharge and discuss it with the various colleagues providing (follow-up) care. In addition, the availability in the outpatient "medicine cabinet" and the possibility of prescribing by the responsible GPs (by telephone) should be checked in advance. In addition, longitudinal focus groups with relevant stakeholders are to be conducted to collect quantitative data as well as qualitative data on the views of those providing and receiving treatment.
There will be cooperation with the Specialized Outpatient Palliative Care Service Muenster to ensure sufficient case numbers and a low rate of missing values through partial use of the standard care data from the "Information System Palliative Care" (ISPC) program they use.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All individual indications for general and specialised palliative care as part of routine clinical practice (e.g.):
Exclusion criteria
Impossibility of understanding the information and declaration of consent.
These patients will receive structured pharmaceutical discharge management from inpatient to outpatient care.
Time frame: 12 months
(I) Number of drug-related problems at the time of discharge according to PCNE (comparison of prospective, actually proposed changes vs. hypothetical number and type of problems at the time of discharge in the retrospective comparison cohort)
Time frame: 12 months
(II) Type of drug-related problems at the time of discharge according to PCNE (comparison of prospective, actually proposed changes vs. hypothetical number and type of problems at the time of discharge in the retrospective comparison cohort)
Time frame: 12 months
Number of contacts made by patients/relatives with SOPC within 7 days of discharge
Time frame: 12 months
Number of readmissions and / or visits to the emergency department within 7 and 14 days after hospital discharge
Time frame: 12 months
Change in patient symptom burden via Integrated Palliative Care Outcome. The total scores using the IPOS can range between 0 and 68 points. The higher the score, the more severe are the patient's symptoms. Scale after 3, 7 and 14 days compared to day 0 (discharge date)
Time frame: 12 months
(I) Number of medication changes suggested by pharmacists according to PCNE
Time frame: 12 months
Adoption rate by the primary care physicians of the pharmacist's proposed changes after PCNE (see primary endpoint)
Time frame: 12 months
(I) Contact made with GPs for medication planning
Time frame: 12 months
(I) Contact made with SOPC for medication planning and (II) resulting changes to discharge medication
Time frame: 12 months
Change in the number of medications in outpatient follow-up care
Time frame: 12 months
Satisfaction of inpatient physicians and those providing further treatment with forward-looking medication planning in 3 focus groups
Time frame: 12 months
(I)Evaluation of further quantitative parameters from ISPC (SOPC)
Time frame: 12 months
(II) Type of medication changes suggested by pharmacists according to PCNE
Time frame: 12 months
(II) Resulting changes to discharge medication following GP contact
Time frame: 12 months
(II) Resulting changes to discharge medication following SOPC contact
Time frame: 12 months
(II) Qualitative assessment of medication changes (classification of drug-related problems according to PCNE)
Time frame: 12 months
(II) Evaluation of further quantitative parameters from the clinical information system (UKM)
Contact information is provided by the study sponsor or research team.
University Hospital Muenster
Other
Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care (Optimierung Der Pharmakologischen Überleitung Von Palliativpatient:Innen Von stationär Nach Ambulant)
Acronym: EntMedPall
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05879211
Brain Diseases, COPD
Durham, North Carolina, United States
View Trial DetailsNCT04916223
Blood-Borne Infections, Brain Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT04351880
COPD, Cancer
Denver, Colorado, United States
View Trial DetailsNCT04466020
COPD, Cancer
London, United Kingdom
View Trial Details